Additionally, intravitreal injection, which is the most common mode of delivery for anti-VEGF drugs, can result in ocular adverse events such as increased intraocular pressure, endophthalmitis, and conjunctival hemorrhage [122]. Here, VEGFA is linked to endophthalmitis.